Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA-190b (miR-190b) is a small, non-coding RNA molecule that regulates gene expression post-transcriptionally by binding to target messenger RNAs, leading to their degradation or translational repression[1][3]. It has been identified as a tumor-suppressive microRNA in non-small cell lung cancer—where it is often down-regulated and associated with poor prognosis—and is notably overexpressed in estrogen receptor-positive (ER+) breast cancers, where high levels correlate with more favorable outcomes[1][3]. miR-190b targets genes involved in DNA repair and cell proliferation, such as HUS1 in lung cancer and RFWD3 in breast cancer, highlighting its role in cancer biology and potential as a biomarker for diagnosis and prognosis[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA-190b (miR-190b).